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Abstract 
Organic anion transporting polypeptides or OATPs are central transporters in the disposition 
of drugs and other xenobiotics. In addition, they mediate transport of a wide variety of 
endogenous substrates. The critical role of OATPs in drug disposition has spurred research 
both in academia and in the pharmaceutical industry. Translational aspects with clinical 
questions are the focus in academia, while the pharmaceutical industry tries to define and 
understand the role these transporters play in pharmacotherapy. The present overview 
summarizes our knowledge on the interaction of food constituents with OATPs, and on the 
OATP transport mechanisms. Further, it gives an update on the available information on the 
structure-function relationship of the OATPs, and finally, covers the transcriptional and 
posttranscriptional regulation of OATPs.
Introduction 
The liver and the kidney are the two most important organs in the metabolism and excretion 
of xenobiotics such as drugs or toxins. In addition, the liver constitutes - after the gut wall - a 
second barrier for the entry of xenobiotics into the systemic circulation. It has been known for 
a long time that certain toxins like phalloidin (from the death cap Amanita phalloides) are 
organ specific. The liver-specific toxicity of phalloidin has been attributed to a transport 
system mediating the uptake of this toxin into hepatocytes (Frimmer, 1982). It was found in 
the perfused rat liver that adding silymarin shortly after phallodin exposure leads to an 
attenuation of the toxic effect of phalloidin as assessed by potassium efflux from the perfused 
liver (Weil & Frimmer, 1970). Uptake experiments into isolated rat hepatocytes lead to the 
postulation of a transport system accepting the bile acid cholate, the cholecystographic agent 
iodipamide and antamanide, which is another toxin from A. phalloides (Petzinger, Joppen, & 
Frimmer, 1983). This postulated transport system was thought to differ from the transport 
system responsible for the hepatocellular uptake of bromosulfophthalein (BSP) based on 
inhibition experiments (Petzinger, et al., 1983). Subsequently, this transport system was 
postulated to be a "multispecific organic anion transporter" (Frimmer & Ziegler, 1988; 
Ziegler, Frimmer, & Fasold, 1984). Of note, earlier studies on perfused rat liver by a different 
group provided evidence for a common uptake mechanism for bilirubin, BSP and indocyanine 
green that could not be inhibited by glycocholic acid (Scharschmidt, Waggoner, & Berk, 
1975). Studies in kidneys demonstrated even earlier that the handling of organic acids and 
organic bases differs (Lotspeich, 1958), again pointing to the presence of more than one 
transport system. Hence, by the early to mid-eighties, the stage was set for concepts that 
functionally discriminated transporters for organic anions from transporters for organic 
cations (reviewed in (van Montfoort et al., 2003). 
The method of expression cloning was introduced for transporters by following the uptake 
activity for the substrate of interest. This lead to the molecular identification of the intestinal 
sodium-dependent uptake system for D-glucose (SGLT1) (Hediger, Coady, Ikeda, & Wright, 
1987). Using BSP as a lead-substrate in conjunction with measurement of chloride dependent 
transport activity (Min, Johansen, Campbell, & Wolkoff, 1991), investigators cloned the first 
sodium-independent organic anion transporter (rOATP1A1) from a rat liver cDNA library 
(Jacquemin, Hagenbuch, Stieger, Wolkoff, & Meier, 1994). In addition to the organic anion 
BSP, this transporter could also mediate the sodium-independent transport of taurocholate and 
cholate, but independently from chloride. It very soon became clear that rOATP1A1 had to 
have closely related homologues (Hagenbuch, Scharschmidt, & Meier, 1996), and this lead to 
the identification of rOATP1A4 by homology screening of a rat brain cDNA library (B. Noe, 
Hagenbuch, Stieger, & Meier, 1997). Functional characterization of rOATP1A1 (Bossuyt, 
Muller, Hagenbuch, & Meier, 1996) and rOATP1A4 (B. Noe, et al., 1997), as well as of their 
human homolog hOATP1A2 (Bossuyt, Muller, & Meier, 1996) demonstrated their broad 
substrate specificity and revealed the ability of OATPs to transport drugs. 
Today, more than 300 members of the OATP (SLCO) transporter superfamily with 11 OATPs 
expressed in humans are known (Hagenbuch & Stieger, 2013). In a human genome wide 
meta-analysis of genes correlating with total serum bilirubin levels, an additional human 
OATP (hOATP1B7 (formerly SLC21A21 or LST-3TM12) was among other proteins 
identified to be associated with higher bilirubin levels. In contrast, in another genome-wide 
association study, hOATP1B7 was not associated with elevated bilirubin levels (Buch et al., 
2010). Importantly, this hOATP1B7 has not been reported to be a functionally active OATP 
so far. Nevertheless, in an analysis of tissue specific expression of various solute transporters 
in rats, rOATP1B7 was reported to be highly expressed at the mRNA level exclusively in rat 
liver (Sreedharan, Stephansson, Schioth, & Fredriksson, 2011). Given the lack of a reported 
function of hOATP1B7, SLCO1B7 may be a pseudogene. 
Substrates of OATPs constitute endogenous molecules, food constituents, drugs and toxins 
(Table 1) as summarized in multiple recent reviews (Hagenbuch & Gui, 2008; Hagenbuch & 
Stieger, 2013; Kalliokoski & Niemi, 2009; Konig, 2011; Kusuhara & Sugiyama, 2009; Roth, 
Obaidat, & Hagenbuch, 2012; Shitara et al., 2013). The importance of OATPs in drug 
disposition is now widely accepted, and interactions with OATPs are  tested during drug 
development by the pharmaceutical industry as requested by regulatory authorities (Fenner et 
al., 2012; Giacomini et al., 2010; S. M. Huang et al., 2008; Tweedie et al., 2013; L. Zhang, 
Huang, & Lesko, 2011; L. Zhang, Strong, Qiu, Lesko, & Huang, 2006; L. Zhang, Zhang, 
Strong, Reynolds, & Huang, 2008). OATPs were identified on their basis to transport BSP, a 
substrate which was thought to be transported (in part) by a postulated bilirubin transport 
system (Clarenburg & Kao, 1973; Scharschmidt, et al., 1975). Many years after their 
identification it was indeed demonstrated that hOATP1B1 and hOATP1B3 could mediate 
bilirubin transport (Briz, Serrano, MacIas, Gonzalez-Gallego, & Marin, 2003; Cui, Konig, 
Leier, Buchholz, & Keppler, 2001). Furthermore, it was also realized that selected OATPs 
play a central role in the disposition of drugs in humans. More importantly, identifying 
OATPs has also significantly contributed to an understanding of the molecular mechanisms of 
pharmacokinetic drug-drug interactions (Konig, Muller, & Fromm, 2013; Shitara, et al., 2013) 
 
Transport of natural products by OATPs 
Besides the well-established transporter-mediated drug-drug interactions that occur in cases 
where a transporter either mediates the uptake of two interacting drugs, or where the uptake of 
one drug is inhibited by the interacting drug, transporter-mediated food-drug interactions have 
recently become a focus in the field of drug disposition. In particular, polyphenols like 
flavonoids, which are found in numerous dietary components, fruit juices and green tea have 
been studied as potential perpetrators of OATP-mediated drug uptake (Bailey, Dresser, Leake, 
& Kim, 2007; Dolton, Roufogalis, & McLachlan, 2012; Fuchikami et al., 2006; X. Wang, 
Wolkoff, & Morris, 2005). Most of these studies investigated to what extent such dietary 
components would affect OATP-mediated substrate transport. In 2002, it was demonstrated 
that grapefruit, orange and apple juice could inhibit OATP-mediated fexofenadine uptake 
(Dresser et al., 2002). In follow-up studies, the same group showed that grapefruit juice 
reduced the oral bioavailability of fexofenadine in healthy human volunteers, possible by 
inhibiting hOATP1A2-mediated fexofenadine uptake in the small intestine (Glaeser et al., 
2007). Furthermore, they showed that naringin - a component of grapefruit juice - was able to 
inhibit completely fexofenadine transport mediated by hOATP1A2 expressed in HeLa cells 
(Bailey, et al., 2007). Besides inhibiting fexofenadine transport, naringin also inhibited 
talinolol transport in hOATP1A2-expressing Xenopus laevis oocytes (Shirasaka et al., 2010), 
and hOATP1A2-mediated uptake of pravastatin and pitavastatin (Shirasaka, Suzuki, Shichiri, 
Nakanishi, & Tamai, 2011). Naringin also inhibited hOATP2B1-mediated uptake of 
pitavastatin, but did not affect pravastatin transport by hOATP2B1 (Shirasaka, et al., 2011). 
The inhibition of OATP-mediated BSP transport by the flavonoids apigenin, kaempferol and 
quercetin was reported to be of competitive nature for intestinal hOATP1A2 and hOATP2B1 
(Mandery et al., 2010), as well as for the liver expressed hOATP1B1 and hOATP1B3 
(Mandery et al., 2012). A standardized extract of milk thistle seeds (silymarin) contains 
several flavonolignans including silibinin, and has been used to treat liver disease since the 
16th century. Legalon SIL is a drug that contains the two diastereomers silibinin A and 
silibinin B (also known as silybin A and silybin B) and is used as an antidote for acute 
amatoxin poisoning (Mengs, Pohl, & Mitchell, 2012). In addition, high dose intravenous 
silibinin is currently investigated in clinical trials for the treatment of hepatitis C infections 
(Ferenci et al., 2008). It was shown in 2006 that silibinin inhibits hOATP1B3-mediated 
uptake of amanitin into hOATP1B3-expressing MDCKII cells (Letschert, Faulstich, Keller, & 
Keppler, 2006). Two recent studies further characterized the interactions of silymarin and 
some of its major constituents with respect to inhibition of OATP-mediated uptake (Kock, 
Xie, Hawke, Oberlies, & Brouwer, 2013; Wlcek, Koller, Ferenci, & Stieger, 2013). In these 
studies silbinin inhibited OATP-mediated substrate uptake. Kock et al. (2013) determined 
IC50 values for silymarin and three of its major constituents, namely silybin A, silybin B and 
silychristin, on hOATP1B1- and hOATP1B3-mediated estradiol-17β-glucuronide and 
hOATP2B1-mediated estrone-3-sulfate uptake. Silybin A and silybin B inhibited OATP-
mediated substrate uptake with IC50 values in the low micromolar range (Kock, et al., 2013). 
For hOATP1B3- and hOATP2B1-mediated uptake of estrone-3-sulfate, silibinin was a 
competitive inhibitor with Ki values of 5µM for hOATP1B3 and 3.6µM for hOATP2B1 
(Wlcek, et al., 2013). However, no direct uptake of any of these flavonoids by any OATP has 
yet been demonstrated. 
Another family of flavonoids that have been studied extensively because of their potential 
beneficial effects on the cardiovascular system (Moore, Jackson, & Minihane, 2009), aging 
(Khurana, Venkataraman, Hollingsworth, Piche, & Tai, 2013) and cancer (Singh, Shankar, & 
Srivastava, 2011) are the green tea catechins, such as epicatechin gallate (ECG) and 
epigallocatechin gallate (EGCG). Both these catechins are modulators of OATP-mediated 
transport (Roth, Timmermann, & Hagenbuch, 2011). ECG and EGCG inhibited the uptake of 
estrone-3-sulfate mediated by hOATP1A2, hOATP1B1 and hOATP2B1 while EGCG 
stimulated estrone-3-sulfate uptake of hOATP1B3. IC50 values for the two compounds ranged 
from about 10 to 100µM. Direct transport experiments performed with OATP-expressing 
CHO cells (for hOATP1B1, hOATP1B3 and hOATP2B1) or HEK293 cells (for hOATP1A2) 
revealed that both ECG, as well as EGCG, are transported substrates of hOATP1A2 and 
hOATP1B3 (Roth, et al., 2011). The signals for hOATP1B1 were not significantly higher 
than the control cells. Kinetic experiments demonstrated saturable uptake of ECG and EGCG 
by hOATP1A2 and hOATP1B3 with Km values between 10 and  39µM (Roth, et al., 2011). 
These transport data were later confirmed using cytotoxicity experiments where incubation of 
control CHO cells or CHO cells expressing hOATP1B1 and hOATP1B3 with increasing 
concentrations of EGCG for 48 hours killed the hOATP1B1- and hOATP1B3-expressing 
cells with IC50 values of 7.7 and 3.2µM, respectively as compared to 271µM for wild-type 
CHO cells (Y. Zhang et al., 2013). The same study also demonstrated that quercetin-3-gallate 
and three additional synthetic quercetin derivatives preferentially killed CHO cells that 
expressed hOATP1B1 or hOATP1B3, data consistent with these quercetin derivatives acting 
as substrates of hOATP1B1 and hOATP1B3 (Y. Zhang, et al., 2013). However, additional 
studies using cell lines expressing individual OATPs are required to determine which of the 
interacting flavonoids indeed are substrates of the respective OATPs. 
 Transport Mechanisms of OATPs 
OATPs as anion exchangers 
OATPs tend to transport amphipathic molecules with a molecular weight of more than 350 Da 
(Roth, et al., 2012). Furthermore, they are capable of mediating the transport of a tightly 
albumin bound substance like bilirubin. Hence, the transport mechanism of OATPs should 
involve the binding of generally amphipathic or even rather hydrophobic substrates followed 
by a translocation process across the plasma membrane. In the case of bilirubin, this process 
most likely involves binding and transport of a molecule with two negative charges because 
the pKa of both carboxylic groups is most likely below 5.0 (Vega-Hissi, Estrada, Lavecchia, 
& Pis Diez, 2013), even though others hypothesized that it may be above 8.0 (Mukerjee & 
Ostrow, 2010). Regardless of this discussion on the protonation state of bilirubin at 
physiologic pH, BSP is a dianionic molecule. Furthermore, many OATP substrates are anions 
(Roth, et al., 2012). Consequently, transporting anionic OATP substrates across the 
membrane involves the movement of one or two negative charges against a negative 
membrane potential of about – 35 mV in hepatocytes (Boyer, Graf, & Meier, 1992). This 
process is energetically unfavorable and not very likely to occur. To date, the transport 
mechanism(s) of OATPs is not known in detail. However, a considerable body of evidence 
supporting an anion-exchange transport mechanism has accumulated. Bicarbonate was the 
first anion to be identified, and can act as a counter ion of rOATP1A1. In HeLa cells 
expressing rOATP1A1, uptake of taurocholate was demonstrated to occur in exchange for 
bicarbonate (Satlin, Amin, & Wolkoff, 1997). Subsequently, trans-stimulation of uptake of 
taurocholate and leukotriene by glutathione was demonstrated for rOATP1A1 (L. Li, Lee, 
Meier, & Ballatori, 1998). rOATP1A1, and rOATP1A4, mediated uptake of taurocholate was 
trans-stimulated by preloading X. laevis oocytes with taurocholate (L. Li, Meier, & Ballatori, 
2000). In the same study, intracellular glutathione stimulated uptake of the uncharged digoxin 
via rOATP1A4, suggesting a rather complex transport mechanism for this OATP. 
Interestingly, S-(2,4-dinitrophenyl)-glutathione (DNP-SG) only stimulated taurocholate 
uptake mediated by rOATP1A4 but not taurocholate uptake mediated by rOATP1A1 (L. Li, et 
al., 2000). In addition, only rOATP1A4 mediated efflux of this glutathione conjugate. In this 
context, it should be kept in mind that digoxin is a substrate for rOATP1A4 but not for 
rOATP1A1 (B. Noe, et al., 1997). Using isolated membrane vesicles with defined sidedness 
from HeLa cells expressing rOATP1A1, investigators demonstrated asymmetric glutathione 
transport (Mittur, Wolkoff, & Kaplowitz, 2002). Uptake into inside-out membrane vesicles 
(representing glutathione efflux from intact cells) was 2- to 3-fold higher than in right-side out 
vesicles (Mittur, et al., 2002). Furthermore, this transport activity was insensitive to changes 
in the membrane potential. A report suggesting that bile acids are cotransported with 
glutathione by hOATP1B3 (Briz et al., 2006) could not be confirmed by others (Mahagita, 
Grassl, Piyachaturawat, & Ballatori, 2007). This is in agreement with the fact that substrate 
transport by hOATP2B1 could not be stimulated by glutathione (Nozawa, Imai, Nezu, Tsuji, 
& Tamai, 2004). More recently, a study testing various OATPs in stably transfected cell lines 
found substrate-mediated bicarbonate efflux for all 5 transporters investigated (Leuthold et al., 
2009). Hence, current evidence supports the concept that OATPs in general work as organic 
anion exchangers with bicarbonate likely being a physiologic counterion. This exchange 
process has not been characterized extensively at a molecular level like reconstituted 
transporters in liposomes. To the best of our knowledge, there is only one publication so far 
that describes the electrophysiologic characterization of OATPs. In this study the authors 
found that  in X. laevis oocytes expressing either hOATP1B1 or hOATP1B3 a current across 
the membrane could be recorded in the presence of different OATP substrates, indicating a 
net movement of a negative charge into the oocytes (Martinez-Becerra et al., 2011). 
Binding sites of OATPs 
While no information of the architecture of the substrate binding site(s) of any OATP is 
currently available, there exists considerable evidence for OATPs having multiple binding 
sites. Kinetic analysis of the transport of estrone-3-sulfate by hOATP1B1 revealed both a high 
and a low affinity transport activity, while the same transporter revealed simple Michaelis-
Menten kinetics for estradiol-17β-glucuronide (Tamai et al., 2001). Similarly, transport of 
estrone-3-sulfate  by hOATP2B1 expressed in X. laevis oocytes has two binding sites 
(Shirasaka, Mori, Shichiri, Nakanishi, & Tamai, 2012), while when expressed in HEK-293 
cells only one binding site was reported (Tamai, et al., 2001). This discrepancy was explained 
by a difference in expression levels, although the potential impact of different expression 
systems (amphibian versus mammalian cells) was not ruled out. Two binding sites for 
estrone-3-sulfate on hOATP1B1 were later independently confirmed (Gui & Hagenbuch, 
2009; J. Noe, Portmann, Brun, & Funk, 2007). Recently, different binding sites of 
hOATP4C1 for estrone-3-sulfate and digoxin were reported (Yamaguchi et al., 2010). Bovine 
OATP1A2 was also reported, in contrast to hOATP1A2, to have two binding sites for estrone-
3-sulfate (X. Liu et al., 2013). 
Additional evidence for the presence of more than one binding site on OATPs was obtained 
from inhibition experiments and reported first for rOATP1A4, which showed a stimulation of 
taurocholate transport by estradiol-17β-glucuronide. However, taurocholate did not stimulate 
the transport of the substrate digoxin (D. Sugiyama, Kusuhara, Shitara, Abe, & Sugiyama, 
2002). Among the human OATPs, hOATP2B1-mediated dehydroepiandrosterone sulfate 
transport could be increased by co-addition of prostaglandin A1 or prostaglandin A2 
(Pizzagalli et al., 2003). Low progesterone also stimulated hOATP2B1-mediated etrone-3-
sulfate transport, but interestingly, at higher progesterone concentrations this stimulation was 
attenuated, demonstrating a biphasic action of progesterone (Grube et al., 2006). The same 
study found classic inhibition of hOATP2B1-mediated estrone-3-sulfate transport by other 
steroids, namely testosterone and mifepristone. However, testosterone has recently been 
reported to stimulate hOATP2B1 (Karlgren et al., 2012). Some dietary components like the 
flavonoid rutin stimulated transport of dehydroepiandrosterone sulfate by hOATP1B1, while 
other flavonoids like biochanin A or luteolin acted as inhibitors (X. Wang, et al., 2005). 
hOATP1B3 transport activity can also be stimulated by green tea extracts or epigallocatechin 
as measured by estron-3-sulfate uptake (Roth, et al., 2011). Silbinin has recently been tested 
with several human organic anion transporters, and found to be a classic inhibitor of the high 
affinity estrone-3-sulfate binding site of hOATP1B1. The low affinity binding site was 
stimulated at low silibinin-concentrations and inhibited at high silibinin concentrations 
(Wlcek, et al., 2013). Finally, the classic drug and PXR agonist clotrimazole stimulated 
hOATP1B3-, but not hOATP1B1-mediated estradiol-17β-glucuronide transport (Gui et al., 
2008). Most interestingly, in the same study, clotrimazole did not affect the hOATP1B3-
mediated transport of estrone-3-sulfate and inhibited fluo-3 uptake. As an additional 
modulating drug, fendiline stimulated hOATPB2B1-mediated estrone-3-sulfate transport 
(Karlgren, et al., 2012). 
Modulation of transport activity 
According to in vitro experiments, the transport activity of hOATP2B1, which is expressed in 
the small intestine and many other organs, is stimulated by an extracellular acidic milieu 
(Kobayashi et al., 2003). Based on an investigation of the pH dependence of 13 rat and human 
OATPs, all but hOATP1C1 were stimulated by an acidic extracellular pH (Leuthold, et al., 
2009). Of note, this stimulation was substrate dependent. For example, while hOATP2B1-
mediated uptake of prostaglandin E2 was not stimulated by an extracellular low pH, transport 
of thyroxine increased at low pH (Leuthold, et al., 2009). Similarly, hOATP2B1-mediated 
pemetrexed transport was strongly stimulated by an acidic pH, while this was not the case for 
BSP (Visentin, Chang, Romero, Zhao, & Goldman, 2012). Along these lines, hOATP1B1-
meditiated transport was also stimulated in a substrate-dependent manner at an acidic pH, and 
may be due to the presence of two different binding sites on this transporter (Leuthold, et al., 
2009). However, other reasons cannot be excluded. Of note, different statins when tested as 
hOATP2B1 substrates show also a variable response to extracellular pH (Varma et al., 2011). 
Kinetic characterization of five OATPs revealed a significantly increased affinity or a trend 
towards increased affinity at low pH (Leuthold, et al., 2009). Mutating a highly conserved 
histidine in the third transmembrane (TM) domain of rOATP1A1 to a glutamine found at the 
same position in hOATP1C1 abolished pH sensitivity of transport, while the reverse 
replacement in hOATP1C1 converted this transporter into a pH-sensitive transporter 
(Leuthold, et al., 2009). Comparing the effect of different pH gradients across the cell 
membrane on the transport activity of rOATP1A1, revealed that transport stimulation was not 
proportional to the magnitude of the pH gradient and the authors suggested a pH-dependent 
modification of the protonation state of the intracellular portion of the transporter (Marin et 
al., 2003). 
Overall, a detailed mechanistic understanding of the transport mechanism(s) and driving 
forces for OATPs is currently lacking. There is however, evidence that OATPs have a rather 
complex transport mechanism, and many (if not most of them) have more than one binding 
site. In addition, the extracellular pH dependence of OATPs, as seen in the acidic 
microclimate in the small intestine (Daniel, Fett, & Kratz, 1989) may mean that they are 
modulated in vivo by nearby acid extruders, such as Na+/H+-exchangers. Consequently, in 
vitro experiments aimed at determining substrate specificities of OATPs expressed in an 
acidic environment should be performed at acidic and neutral pH. 
 
Structural information on OATPs 
General structure 
Given that all mammalian OATPs (650 to 700 amino acids) have an amino-acid sequence 
identity of more than 30% to their more distant relatives (Hagenbuch & Meier, 2003), it is 
highly likely that they all share the same overall TM domain structure. Initial hydrophobicity 
analysis of rOATP1A1 and hOATP1A2 predicted the presence of 10 to 12 TM domains with 
both N- and C-terminal ends on the cytoplasmic side (Jacquemin, et al., 1994; Kullak-Ublick 
et al., 1995). The intracellular localization of the C-terminal end was experimentally 
confirmed using an antibody against the C-terminal end of hOATP1B3. Immunostaining was 
only observed in detergent permeabilized cells (Abe et al., 2001), confirming a topology with 
both termini on the cytoplasmic side of the membrane. In 2008, the 12 TM domain structure 
of rOATP1A1 was confirmed using site-directed mutagenesis of putative N-glycosylation 
sites (P. Wang, Hata, Xiao, Murray, & Wolkoff, 2008). It was demonstrated that rOATP1A1 
was N-glycosylated in the second and fifth extracellular loop, and that the unglycosylated 
protein was retained intracellularly and thus caused reduced transport function (P. Wang, et 
al., 2008). Similar results were recently published for hOATP1B1 (Yao et al., 2012). The 
authors demonstrated that hOATP1B1 is N-glycosylated in the second and fifth extracellular 
loop, and that the unlgycosylated protein is retained in the endoplasmic reticulum. Thus, it is 
likely that all mammalian OATPs are N-glycosylated in these two extracellular loops. 
Disulfide bonds can also have an effect on the proper folding and function of a protein. Based 
on results from site-directed mutagenesis of the 10 conserved cysteine residues in the large 
extracellular loop 5 of hOATP2B1, all 10 cysteine residues are normally disulfide bonded and 
these disulfide bonds are important for the proper targeting of hOATP2B1 to the plasma 
membrane (Hanggi, Grundschober, Leuthold, Meier, & St-Pierre, 2006). 
Role of conserved amino acids 
In the absence of a crystal structure for any of the OATPs, homology modeling has been 
performed by several groups and the respective models were used to test structural 
hypotheses. The first of such models was described in 2005 and predicted the presence of a 
central pore in hOATP1B3 and hOATP2B1 that contained several positively charged 
arginine, lysine and histidine residues (Meier-Abt, Mokrab, & Mizuguchi, 2005). The role of 
some of these conserved positively charge amino acids was then tested in site-directed 
mutagenesis studies using hOATP1B1 (Weaver & Hagenbuch, 2010) and hOATP1B3 
(Glaeser, Mandery, Sticht, Fromm, & Konig, 2010; Mandery et al., 2011) as a template. In 
hOATP1B1, mutations at R57, K361 and R580 all decreased the affinity for estradiol-17β-
glucuronide and increased the affinity for BSP, suggesting that these amino acid residues are 
part of the substrate binding sites. Mutations of the intracellular K90, H92 and R93 mainly 
affected the maximal transport activity. Mutants R181K and R580A also reduced surface 
expression of hOATP1B1 (Weaver & Hagenbuch, 2010). K41, K361 and R580 are important 
for substrate transport of hOATP1B3 (Glaeser, et al., 2010; Mandery, et al., 2011) while 
K399 is necessary for normal surface expression (Mandery, et al., 2011). Because hOATP1B1 
and hOATP1B3 have overlapping substrate specificities, it is interesting to note that both 
K361 and R580 are important for the transport function of both hOATP1B1 and hOATP1B3. 
Individual transmembrane domains 
According to several studies, certain amino acids in TM domains 2, 6, 8, 9 and 10 are 
important for the function of hOATP1B1 (Gui & Hagenbuch, 2009; J. Huang et al., 2013; N. 
Li et al., 2012; Miyagawa, Maeda, Aoyama, & Sugiyama, 2009) and hOATP1B3 (Gui & 
Hagenbuch, 2008). In TM2, charged amino acids D70 and E74 seem critical for estrone-3-
sulfate transport (N. Li, et al., 2012). While D70 seems to decrease both high- and low-
affinity estron-3-sulfate uptake, E74 seems only important for high-affinity transport. In 
addition, mutant G76A showed reduced protein expression when compared to wild-type 
hOATP1B1 and the other mutants (N. Li, et al., 2012). The effect of two tryptophan residues 
within the OATP family signature at the extracellular half of TM6 of hOATP1B1 was tested 
by mutating the tryptophan to alanine residues, and the effect of these mutations on estrone-3-
sulfate transport was tested. While wild-type hOATP1B1 has a high- and a low-affinity 
binding site for estrone-3-sulfate resulting in biphasic kinetics (Gui & Hagenbuch, 2009; J. 
Noe, et al., 2007; Tamai, et al., 2001), the W258A mutant showed only a single binding 
component with a Km value in between the high- and low-affinity values of wild-type 
hOATP1B1 (J. Huang, et al., 2013). In contrast, the W259A mutant retained biphasic kinetics 
for estrone-3-sulfate with a higher Km value for the high-affinity but a similar Km value for 
the low-affinity component as compared to wild-type hOATP1B1 (J. Huang, et al., 2013). 
Several groups utilized a chimera approach and constructed chimeras using hOATP1B1 and 
hOATP1B3 (Degorter, Ho, Leake, Tirona, & Kim, 2012; Gui & Hagenbuch, 2008, 2009; 
Miyagawa, et al., 2009). Replacing TM8 in hOATP1B1 with that of hOATP1B3 resulted in a 
protein with an 18-fold higher Km value for estrone-3-sulfate than that of wild-type 
hOATP1B1 and abolished estradiol-17β-glucuronide transport (Miyagawa, et al., 2009). 
Replacing TM9 in hOATP1B1 with that of hOATP1B3 did not change the transport of 
estradiol-17β-glucuronide, but increased the Km value for estron-3-sulfate 7.4-fold 
(Miyagawa, et al., 2009). TM10 was identified as being important for substrate transport in 
both hOATP1B1 (Gui & Hagenbuch, 2009) and hOATP1B3 (Gui & Hagenbuch, 2008). 
Follow-up site-directed mutagenesis studies identified several amino acids (L545, F546, L550 
and S554) within TM10 that when replaced with the hOATP1B3 counterparts converted 
hOATP1B1 from a biphasic to a monophasic estron-3-sulfate transporter (Gui & Hagenbuch, 
2009). Similar experiments with hOATP1B3 resulted in the identification of Y537, S545 and 
T550 in TM10 as being important for the hOATP1B3 selective substrate CCK-8 (Gui & 
Hagenbuch, 2008). Finally, in a recent report, hOATP1B1 was converted into an hOATP1B3-
like transporter that was able to transport CCK-8 when the three amino acid residues A45 in 
TM1, L545 in TM10 and T615 in extracellular loop 6 were replaced by the corresponding 
hOATP1B3 residues (Degorter, et al., 2012). Although this triple mutant showed uptake of 
CCK-8, its intrinsic clearance was about 8-fold smaller than the intrinsic clearance of 
hOATP1B3.  
Taken together, available data are consistent with OATPs being 12TM domain proteins with 
both termini on the cytoplasmic side. Furthermore, OATPs seem to have an aqueous pore that 
can accept several substrates with overlapping and partially distinct binding sites, which 
consist in part of conserved positively charged amino acids. Future experiments using higher 
resolution homology modeling will help to better delineate the location of functionally 
important amino acid residues until the three-dimensional structure has been elucidated either 
using crystallography and/or NMR spectroscopy. In addition, the current hypothetical models 
will have to be improved by investigating which amino acid residues within the postulated 
TM domains are accessible from the outside or the inside in the absence or presence of 
substrates. 
 
Regulation of OATPs 
Transcriptional regulation of OATPs 
Regulation of gene expression at the transcriptional level for adaptive purposes is governed by 
transcription factors, which act as sensors for endogenous ligands and xenobiotics (Germain, 
Staels, Dacquet, Spedding, & Laudet, 2006). Hence, at the level of the intact organism, 
transcriptional regulation of gene expression can be studied by applying xenobiotics to animal 
models and then analyzing the expression of genes of interest. Such studies were performed 
with knockout mice lacking the genes for nuclear receptors and demonstrated that expression 
of SLCOs can be up-regulated by ligands for the arylhydrocarbon receptor AhR, the 
constitutive androgen receptor CAR, the pregnane X receptor PXR and the farnesoid X 
receptor FXR (Klaassen & Aleksunes, 2010; Meyer zu Schwabedissen & Kim, 2009). 
However, such studies do not demonstrate that the transcription factors investigated bind 
directly to the gene of interest. Liver-enriched transcription factors (Schrem, Klempnauer, & 
Borlak, 2002) belong to different classes of transcriptional regulators. They are also called 
hepatocyte nuclear factors and are known to positively or negatively regulate the transcription 
of SLCO genes (reviewed in (Geier, Wagner, Dietrich, & Trauner, 2007; Hagenbuch & 
Stieger, 2013; Klaassen & Aleksunes, 2010; Stieger & Geier, 2011; Svoboda, Riha, Wlcek, 
Jaeger, & Thalhammer, 2011)). 
The bile acid sensor FXR can directly and indirectly modulate the expression of SLCO genes, 
leading either to up-regulation or to down-regulation of gene transcription of the respective 
genes (Eloranta & Kullak-Ublick, 2008; Godoy et al., 2013). Such studies may also lead to 
conflicting results. Expression of SLCO1B1 was reported to be reduced via FXR-dependent 
repression of HNF-1 (Jung, Elferink, Stellaard, & Groothuis, 2007), and increased via direct 
up-regulation by FXR (Meyer Zu Schwabedissen et al., 2010). Other nuclear receptors like 
PXR, CAR and LXR are also known to regulate the expression of SLCO genes. (Godoy, et al., 
2013; Hagenbuch & Stieger, 2013; Klaassen & Aleksunes, 2010). Lately, the vitamin D 
receptor VDR has been added to this list, and it has been shown to activate the expression of 
SLCO1A2 (Eloranta, Hiller, Juttner, & Kullak-Ublick, 2012). As ligands for nuclear receptors 
are also substrates for OATPs (Gui, et al., 2008), the transporters may, to some extent, control 
the access of nuclear receptor ligands to their own genes. Hypoxia leads to the expression of 
hypoxia-inducible factors, which in turn regulate transcription (Schodel, Mole, & Ratcliffe, 
2013). Interestingly, a cancer-specific variant of hOATP1B3 was found to be induced by 
hypoxia and a promoter construct of SLCO1B3 was demonstrated to bind HIF-1α (Han, Kim, 
Thakkar, Kim, & Lee, 2013). Another research group identified two functional HIF-response 
elements in the promoter of SLCO1B3 (Ramachandran et al., 2013). 
Tissue-specific regulation of protein expression is frequently associated with epigenetic 
regulation. In mice, a genome-wide DNA-methylation profiling revealed CpG dinucleotides 
in the area of the transcriptional start site of hOATP1B2 (Imai et al., 2009). An extension of 
this analysis revealed CpG islands around the translation start sites of mOATP1A1, 
mOATP1A6, mOATP1C1 and mOATP1A4; comparable findings were obtained for 
hOATP1B1 and hOATP1B3 (Imai, Kikuchi, Kusuhara, & Sugiyama, 2013). The different 
methylation patterns are suggested to be involved in the tissue-specific expression of the 
investigated OATPs. In Caco-2 cells, heterochromatin protein 1β up-regulation leads to an 
up-regulation of SLCO1B3 among other targets (Tell, Wang, Blunier, & Benya, 2011). 
Expression of a cancer-specific variant of hOATP1B3 in various cancer cell lines is critically 
dependent on the methylation pattern around the translational start site (Imai et al., 2013), as 
well as the expression of SLCO2A1 in human head and neck squamous cell carcinoma (Zolk 
et al., 2013). 
Posttranslational regulation of OATPs 
At the post-transcriptional level, ATP-induced functional down-regulation of rOATP1A1 is 
mediated by serine phosphorylation (Glavy, Wu, Wang, Orr, & Wolkoff, 2000). This 
phosphorylation is not associated with subsequent internalization of rOATP1A1. In a 
subsequent study, S634 and S635 of rOATP1A1 were found to be phosphorylated (Xiao, 
Nieves, Angeletti, Orr, & Wolkoff, 2006). This study was extended to rOATP1A4 in X. laevis 
oocytes, where PKC-dependent inhibition of transport activity of rOATP1A1 and rOATP1A4 
was observed (Guo & Klaassen, 2001). Plasma membrane expression of hOATP1B1 in COS7 
and HEK293 cells on the other hand, was stimulated after treatment of the cells with 8-Br-
cAMP and this stimulation could be blocked by protein kinase A-inhibitors (Sun, Ponamgi, 
Boyer, & Suchy, 2008). Using protein kinase A inhibitors alone, plasma membrane 
expression of hOATP1B1 was reduced. In contrast, hOATP2B1 stably transfected in MDCK 
cells could be phosphorylated in a protein kinase C-dependent manner, thereby leading to a 
rapid internalization of hOATP2B1 (Kock et al., 2010). hOATP1A2 expressed in COS-7 cells 
was also internalized from the plasma membrane in a protein kinase C-dependent manner by a 
process requiring ongoing clathrin-dependent endocytosis (Zhou, Lee, Krafczyk, Zhu, & 
Murray, 2011). According to a recent paper, short-term treatment of either Caco-2 cells or rats 
with amiodarone leads to an increased surface expression of hOATP2B1 in Caco-2 cells and 
of rOATP2B1 at the brush border membrane of rat jejunum and ileum as assessed by Western 
blotting (Segawa et al., 2013). 
Scaffolding of OATPs 
Protein-protein interactions leading to scaffolds at the plasma membrane can also be 
considered a posttranslational regulatory mechanism. A yeast two-hybrid screen using the C-
terminus of various drug transporters indeed revealed an interaction of hOATP1A2, 
hOATP1C1 and hOATP3A1 with PDZ proteins (Kato, Yoshida, Watanabe, Sai, & Tsuji, 
2004). PDZ adaptors are well known to be involved in the regulation of transport proteins by 
regulating their plasma membrane expression level (Sugiura, Shimizu, Kijima, Minakata, & 
Kato, 2011). rOATP1A1 was shown in a cell-culture system in conjunction with 
coimmunoprecipitation to interact with PDZK1 (P. Wang et al., 2005). Most interestingly, 
mice with a disrupted gene for PDZK1 showed a strongly reduced expression of mOATP1A1 
at the hepatocyte basolateral membrane, with an increased cytoplasmic localization of 
mOATP1A1 (P. Wang, et al., 2005). These mice display a slightly reduced fractional uptake 
rate for the prototypic OATP substrate BSP and about a 25 % increased plasma half-life (P. 
Wang, et al., 2005). PDZK1 mediates the trafficking to the plasma membrane by a selective 
recruitment of microtubule-based motor proteins (W. J. Wang, Murray, & Wolkoff, 2013). 
Others found a reduced estrone-3-sulfate uptake into the portal vein of mice lacking PDZK1 
without a change in systemic circulation (Sugiura et al., 2010). Using an Ussing-chamber 
setup with small intestine from the same mice, uptake of estrone-3-sulfate from the apical 
lumen into intestinal tissue was significantly reduced. This study confirmed and found 
interactions of the C-terminus of mouse OATPs with different PDZ proteins (Sugiura, et al., 
2010). Interactions of human and mouse OATPs with the different adaptor proteins are 
summarized in Table 2 (Sugiura, et al., 2010). 
In summary, OATPs are extensively regulated at the transcriptional and posttranscriptional 
levels. Given that many OATPs are xenobiotic transporters and hence involved in the 
disposition and elimination of potentially toxic xenotiotics, this extensive network of 
regulatory processes acting on OATPs may contribute to protect organisms from toxic actions 
of xenobiotics. Regulation of gene expression by xenosensors like the nuclear receptors CAR 
or PXR is key in the detoxification of xenobiotics by metabolizing as well as exporting them 
for excretion. Hence, common transcriptional regulatory mechanisms for OATPs as cellular 
xenobiotic uptake systems with down-stream metabolism and metabolite export is an effective 
functional network preventing cells from being overloaded with potentially harmful 
compounds. 
Although single nucleotide polymorphisms are not in a strict sense a regulatory mechanism 
because they cannot be modified by cells, there is now ample evidence that polymorphic 
variants of OATPs are abundant in humans and may contribute significantly to changes in 
drug disposition. They also constitute risk factors for adverse drug actions. This topic has 
lately been extensively reviewed (Clarke & Cherrington, 2012; Gong & Kim, 2013; 
Hagenbuch & Stieger, 2013; Nakanishi & Tamai, 2012; Niemi, 2010; Niemi, Pasanen, & 
Neuvonen, 2011; Shitara, et al., 2013; Stieger & Meier, 2011; Zair, Eloranta, Stieger, & 
Kullak-Ublick, 2008). 
 
Outlook 
The role of OATPs in drug and xenobiotic disposition is now well established and accepted 
(Fenner, et al., 2012). Due to their wide expression in most tissues, they govern the access (or 
exit) of many endogenous and exogenous compounds in a vast variety of cell types and 
associated tissues and organs. Lately, the importance of transporters, including OATPs, to 
monitoring organ function and to visualize them has been prominently recognized (Hoekstra 
et al., 2013; Stieger, Heger, de Graaf, Paumgartner, & van Gulik, 2012; Van Beers, Pastor, & 
Hussain, 2012). Imaging is widely used to diagnose and manage a variety of diseases 
including neurologic disorders or cancer. Because OATPs are found to be expressed in many 
different cancers (Cutler & Choo, 2011; Obaidat, Roth, & Hagenbuch, 2012; Sissung, Reece, 
Spencer, & Figg, 2012), they are an important diagnostic marker.. They may also be used as 
entry sites for drugs used to fight cancer (T. Liu & Li, 2013) an important aspect that certainly 
has a large potential for further anticancer drug development. As OATPs are very important in 
drug disposition, direct determination of their transport activity in vivo is highly desirable. 
With the rapid progress in the development of better imaging tools such as positron emission 
tomography or single-photon emission computed tomography (Mairinger, Erker, Muller, & 
Langer, 2011; Y. Sugiyama & Yamashita, 2011), such a goal should be achievable. In order 
to successfully develop novel OATP substrates to be used for in vivo transporter function 
determination, a tight coordination of studies performed in vitro (e.g. by using heterologous 
expression systems) and in vivo experiments will be necessary, whereby special consideration 
has to be given to the overlapping substrate specificity of OATPs. As OATPs are also the 
entry sites for toxins, (e.g. the ones present in the mushroom death cap), there potential as 
drug target for the treatment of patients after ingestion of toxic substances could certainly be 
further developed. Because drug effects and adverse drug actions critically depend on the 
intracellular drug concentrations (Chu et al., 2013), a major effort has to be made in 
elucidating the exact transport mechanism as well as the potential driving forces of OATPs. 
This knowledge will be critical for better understanding and potentially even predicting 
cellular effects of drugs. Lastly, there is currently no information about the high-resolution 
structure of OATPs available. Such information is critical for understanding the molecular 
transport mechanisms of OATPs. The emergence of new tools like cryo-electronmicroscopy 
(Milne et al., 2013), and its integration with structure determination by NMR or x-ray 
crystallography will advance this challenging area of OATP research. 
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Table 1: Substrate classes of human OATPs  
 
OATP Endogenous 
substrates 
Xenobiotic substrates Model substrates 
OATP1A2 bile salts, bilirubin, 
steroid hormone 
metabolites, thyroid 
hormones and 
metabolites,  
liver function markers, 
β-blockers, statins, 
antiviral drugs, 
antibiotics, mushroom 
toxins, neuropeptides, 
anticancer drugs 
Bromosulfophthalein 
Estrone-3-sulfate 
Fexofenadine 
 
 
OATP1B1 bile salts, bilirubin, 
steroid hormone 
metabolites, thyroid 
hormones and 
metabolites, 
inflammatory 
mediators 
liver function markers, 
mushroom toxins, 
statins, sartanes, 
antibiotics, antiviral 
drugs, anticancer 
drugs 
Bromosulfophthalein 
Estradiol-17β-
glucuronide 
Estrone-3-sulfate 
Pitavastatin 
Atorvastatin 
Pravastatin 
Rosuvastatin 
Valsartan 
OATP1B3 bile salts, bilirubin, 
steroid hormone 
metabolites, thyroid 
hormones, 
inflammatory 
mediators 
liver function markers, 
mushroom toxins, 
statins, sartanes, 
antibiotics, antiviral 
drugs, anticancer 
drugs, peptides 
Bromosulfophthalein 
Cholecystokinin 
extapeptide 
Estradiol-17β-
glucuronide 
Valsartan 
OATP1C1 thyroid hormones and 
metabolites, steroid 
hormone metabolites 
liver function markers Thyroxine 
OATP2A1 inflammatory 
mediators 
 Prostaglandines 
(PGE1, PGE2, 
PGE2α) 
OATP2B1 steroid hormone 
metabolites, 
inflammatory 
liver function markers, 
statins,  
Bromosulfophthalein 
Estron-3-sulfate 
mediators, thyroid 
hormones 
OATP3A1 steroid hormone 
metabolites, 
inflammatory 
mediators, thyroid 
hormones 
 PGE1 
PGE2 
OATP4A1 bile salts, steroid 
hormone metabolites, 
thyroid hormones,  
 Triiodothyronine 
Taurocholate 
OATP4C1 bile salts, steroid 
hormone metabolites, 
thyroid hormones 
 Estrone-3-sulfate 
Digoxin 
 
For a detailed recommendation of OATP probe substrates and inhibitors, please refer to: 
(Brouwer et al., 2013) 
  
Table 2: Demonstrated interaction of OATPs with adaptor proteins 
OATP PDZK1 PDZK2 NHERF1 NHERF2 IKEPP  
rOATP1A1 yes     (P. Wang, et al., 
2005) 
mOATP1A1 yes yes yes yes  (Sugiura, et al., 2010) 
hOATP1A2 yes  yes yes yes (Kato, et al., 2004) 
mOATP1A4 yes yes yes yes  (Sugiura, et al., 2010) 
mOATP1A5 yes yes yes yes  (Sugiura, et al., 2010) 
mOATP1A6 yes yes yes yes  (Sugiura, et al., 2010) 
mOATP1B2  yes yes yes  (Sugiura, et al., 2010) 
hOATP1C1     yes (Kato, et al., 2004) 
mOATP1C1 yes yes yes yes  (Sugiura, et al., 2010) 
mOATP2A1  yes    (Sugiura, et al., 2010) 
mOATP2B1  yes  yes  (Sugiura, et al., 2010) 
hOATP3A1   yes yes yes (Kato, et al., 2004) 
mOATP3A1 yes yes  yes  (Sugiura, et al., 2010) 
 
NHERF: Na+/H+ exchanger regulatory factor 
IKEPP: intestinal and kidney-enriched PDZ protein 
yes means that an interaction was demonstrated, an empty cell means that the respective 
OATP did not interact or an interaction was not demonstrated  
 
